<!DOCTYPE html>
<!--
    Copyright (c) 2012-2016 Adobe Systems Incorporated. All rights reserved.

    Licensed to the Apache Software Foundation (ASF) under one
    or more contributor license agreements.  See the NOTICE file
    distributed with this work for additional information
    regarding copyright ownership.  The ASF licenses this file
    to you under the Apache License, Version 2.0 (the
    "License"); you may not use this file except in compliance
    with the License.  You may obtain a copy of the License at

    http://www.apache.org/licenses/LICENSE-2.0

    Unless required by applicable law or agreed to in writing,
    software distributed under the License is distributed on an
    "AS IS" BASIS, WITHOUT WARRANTIES OR CONDITIONS OF ANY
     KIND, either express or implied.  See the License for the
    specific language governing permissions and limitations
    under the License.
-->
<html>

<head>
    <meta charset="utf-8" />
    <meta name="format-detection" content="telephone=no" />
    <meta name="msapplication-tap-highlight" content="no" />
    <meta name="viewport" content="user-scalable=no, initial-scale=1, maximum-scale=1, minimum-scale=1, width=device-width" />
    <!-- This is a wide open CSP declaration. To lock this down for production, see below. -->
    <meta http-equiv="Content-Security-Policy" content="default-src * 'unsafe-inline'; style-src 'self' 'unsafe-inline'; media-src *" />
    <!-- Good default declaration:
    * gap: is required only on iOS (when using UIWebView) and is needed for JS->native communication
    * https://ssl.gstatic.com is required only on Android and is needed for TalkBack to function properly
    * Disables use of eval() and inline scripts in order to mitigate risk of XSS vulnerabilities. To change this:
        * Enable inline JS: add 'unsafe-inline' to default-src
        * Enable eval(): add 'unsafe-eval' to default-src
    * Create your own at http://cspisawesome.com
    -->
    <!-- <meta http-equiv="Content-Security-Policy" content="default-src 'self' data: gap: 'unsafe-inline' https://ssl.gstatic.com; style-src 'self' 'unsafe-inline'; media-src *" /> -->

    <link rel="stylesheet" type="text/css" href="css/index.css" />
    <title>Late Stage MSS-CRC Trial Finder</title>
</head>

<body>
    <div class="app">
    </div>
    <script type="text/javascript" src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.2.1/jquery.min.js"></script>
    <script type="text/javascript" src="https://cdnjs.cloudflare.com/ajax/libs/mustache.js/2.3.0/mustache.min.js"></script>
    <script type="text/javascript" src="cordova.js"></script>
    <script type="text/javascript" src="js/index.js"></script>
    <script type="text/javascript" src="js/dataHandler.js"></script>
    <script type="text/javascript" src="js/dataModel.js"></script>
    <script type="text/javascript" src="js/pageModel.js"></script>
    <script type="text/javascript" src="js/splashScreen.js"></script>
    <script type="text/javascript" src="js/wizard.js"></script>
    <script type="text/javascript" src="js/trialList.js"></script>
    <script type="text/javascript" src="js/trialView.js"></script>
    <script type="text/javascript">
        var controller;
        new DataHandler('http://trialfinder.fightcrc.org/').loadTrials().done(function(trials) {
            var data = new Data(trials,
        /*var data = new Data([new Trial(
            'NCT01061515', true, false, 'CRC-directed Trial', true, 'A novel technique CRC-directed trial. This study is to test escalating doses of *intraperitoneal (IP)-dosed* oxaliplatin in conjunction with systemic bevacizumab and capecitabine in patients with *Peritoneal Carcinomatosis (PC)* from CRC that have been adequately cytoreduced and have undergone a peritoneal scan demonstrating patency of at least one of the intraperitoneal ports that were placed at the time of debulking.',
            [], ['http://www.siteman.wustl.edu'], 'A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer',
            'Recruiting', ['Missouri'], '2010-02-01', '2018-01-04', 'Phase 1',
            ['Bevacizumab', 'Capecitabine', 'Intraperitoneal Oxaliplatin'],
            ['Eloxatin', 'Avastin', 'Xeloda'],
            '-  To determine the maximum tolerated dose of IP oxaliplatin with systemic intravenous bevacizumab and oral capecitabine after adequate surgical debulking and peritoneal scan documenting function of intraperitoneal ports in patients with peritoneal carcinomatosis of appendiceal or colorectal etiology.\n-  To assess the safety and tolerability of repeated delayed intraperitoneal chemotherapy with oxaliplatin and systemic intravenous bevacizumab and oral capecitabine after adequate surgical debulking and peritoneal scan documenting function of intraperitoneal ports in patients with peritoneal carcinomatosis of appendiceal or colorectal etiology.\n-  To describe the progression rate, progression-free survival and overall survival in patients treated with this regimen.',
            undefined, undefined, 'Any',
            '-  Histological Diagnosis: Patients must have a histologically documented peritoneal carcinomatosis from either colorectal or appendiceal adenocarcinoma.\n-  Prior Surgical Debulking: Patients must have undergone debulking surgery with peritonectomy and have been allowed at least 4 weeks to recover prior to receiving chemotherapy.\n-  Port Placement: Intraperitoneal ports may be placed during or at any time separate from surgical debulking. Provided the patient has been allowed at least 4 weeks to recover from surgical debulking, no additional recovery time is required for port placement.\n-  Active port: Patients must undergo a peritoneal scan documenting at least one working intraperitoneal port prior to receiving chemotherapy.\n-  Patients may have received prior chemotherapy.\n-  Age: Patients must be ≥18 years of age. Because no dosing or toxicity data are currently available on the use of oxaliplatin in patients <18 years of age.\n-  Performance Status: (Eastern cooperativeOncology Group) ECOG 0-2.\n-  Recovery from Intercurrent Illness: Patients must have recovered from uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmias.\n-  Informed Consent: All patients must be consented prior to chemotherapy. The patient should not have any serious medical of psychiatric illness that would prevent either the giving of informed consent or the receipt of treatment.\n-  Hematological Status:\n-  absolute neutrophil count ≥1,500/mm³\n-  platelet count ≥100,000/mm³\n-  hemoglobin ≥8 g/dl.\n-  Hepatic function:\n-  Total bilirubin must be <2X the institutional upper limit of normal (ULN)\n-  Transaminases (SGOT and/or SGPT) must be ≤3X the institutional upper limit of normal (ULN)\n-  Alkaline phosphatase must be ≤4X the institutional upper limit of normal (ULN)\n-  Renal Function: Patients must have adequate renal function prior to chemotherapy defined as serum creatinine ≤ 2.0 mg/dl or creatinine clearance ≥60 ml.min/1.73 m² for patients with creatinine levels above 2.0 mg/dl.',
            '-  Pregnant or breast feeding: For all sexually active patients, the use of adequate contraception (hormonal or barrier method of birth control) will be required during therapy, prior to study entry, and for the duration of study participation.  Non-pregnant status will be determined in all women of childbearing potential.\n-  Prior history of hypersensitivity reactions to oxaliplatin, bevacizumab, 5-FU or capecitabine.\n-  Gastrointestinal ailments that may alter the absorption of oral medications (i.e.  bowel obstruction, short-gut syndrome).\n-  Patients receiving antiretroviral therapy Highly Active Anti Retroviral Treatment (HAART) for HIV infection are excluded from the study because of possible pharmacokinetic interactions. Appropriate studies will be undertaken in patients receiving HAART therapy, when indicated.\n-  Patients with Grade 2 or higher peripheral neuropathy.')], */
            new Preferences({}, {'wizard': 0, 'lastVisited': '2017-12-01'}));
            controller = new Controller([
                new SplashScreen(),
                new Wizard(),
                new TrialList(),
                new TrialView()
            ], data);
            app.initialize(controller);
        });
    </script>
</body>

</html>
